Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Ningning Niu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4210-0136; OpenAlex author ID A5086377363. Sources: OpenAlex.

Their work

Papers
13 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
62
Papers, trials and grants by year

2019: 2 papers · 2020: 1 paper · 2021: none · 2022: 3 papers · 2023: 1 paper · 2024: 2 papers · 2025: 2 papers · 2026: 2 papers

Papers 13

  1. A peritumoral microenvironment engaged by Reg-EXTL3 axis fosters nerve-cancer interactions in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.neuron.2026.03.039↗
  2. Epigenetic dysregulation and microenvironment remodeling in pancreatic cancer. Co-author DOI 10.1016/j.trecan.2026.01.011↗
  3. Targeting pancreatic cancer glutamine dependency confers vulnerability to GPX4-dependent ferroptosis. Co-author DOI 10.1016/j.xcrm.2025.101928↗
  4. Noninvasive Computed Tomography-Based Quantification of Tumor Fibrosis Predicts Pancreatic Cancer Response to Gemcitabine/Nab-Paclitaxel. Co-author DOI 10.34133/research.0937↗
  5. SIN3B Loss Heats up Cold Tumor Microenvironment to Boost Immunotherapy in Pancreatic Cancer. Co-author DOI 10.1002/advs.202402244↗
  6. Tumor cell-intrinsic epigenetic dysregulation shapes cancer-associated fibroblasts heterogeneity to metabolically support pancreatic cancer. Co-author DOI 10.1016/j.ccell.2024.03.005↗
  7. Oncogenic KRAS triggers metabolic reprogramming in pancreatic ductal adenocarcinoma. First author DOI 10.2478/jtim-2022-0022↗
  8. Smad4 Deficiency Promotes Pancreatic Cancer Immunogenicity by Activating the Cancer-Autonomous DNA-Sensing Signaling Axis. Co-author DOI 10.1002/advs.202103029↗
  9. Glycolysis addiction compensating for a defective pentose phosphate pathway confers gemcitabine sensitivity in SETD2-deficient pancreatic cancer. Last author DOI 10.1016/j.bbrc.2022.05.047↗
  10. SULF2 enhances GDF15-SMAD axis to facilitate the initiation and progression of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2022.215693↗
  11. Perineural Invasion Reprograms the Immune Microenvironment through Cholinergic Signaling in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-19-2689↗
  12. CD90 highly expressed population harbors a stemness signature and creates an immunosuppressive niche in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2019.03.051↗
  13. THZ1 reveals CDK7-dependent transcriptional addictions in pancreatic cancer. Co-author DOI 10.1038/s41388-019-0701-1↗

Closest collaborators

The 25 strongest of 62 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jing Xue · 12 shared papers, 2019–2026 · strength 2.24
  2. Xuqing Shen · 5 shared papers, 2022–2025 · strength 0.96
  3. Ping Lu · 7 shared papers, 2019–2025 · strength 0.92
  4. Yongwei Sun · 7 shared papers, 2019–2024 · strength 0.90
  5. Yingying Tang · 3 shared papers, 2024–2025 · strength 0.59
  6. Minwei Yang · 4 shared papers, 2019–2024 · strength 0.47
  7. Liwei Wang · 3 shared papers, 2019–2025 · strength 0.39
  8. Hong‐Fei Yao · 2 shared papers, 2022–2026 · strength 0.34
  9. Juanjuan Shi · 3 shared papers, 2019–2022 · strength 0.32
  10. Ruizhe He · 3 shared papers, 2019–2022 · strength 0.30
  11. Li-Peng Hu · 2 shared papers, 2020–2026 · strength 0.28
  12. Shu‐Heng Jiang · 2 shared papers, 2020–2026 · strength 0.28
  13. Tiebo Mao · 1 shared paper, 2025 · strength 0.22
  14. Juanjuan Shi · 2 shared papers, 2019–2022 · strength 0.21
  15. Jian‐Yu Yang · 2 shared papers, 2020–2022 · strength 0.20
  16. Xueliang Fu · 2 shared papers, 2020–2022 · strength 0.20
  17. Yongsheng Jiang · 2 shared papers, 2020–2022 · strength 0.20
  18. Dejun Liu · 2 shared papers, 2020–2022 · strength 0.20
  19. Yan‐Miao Huo · 2 shared papers, 2020–2022 · strength 0.20
  20. Massimiliano Mazzone · 1 shared paper, 2024 · strength 0.20
  21. Zhengyan Zhang · 1 shared paper, 2024 · strength 0.20
  22. Junyi Xu · 1 shared paper, 2024 · strength 0.20
  23. Yu-Heng Zhu · 1 shared paper, 2026 · strength 0.20
  24. Jiang Chongyi · 1 shared paper, 2026 · strength 0.20
  25. Luju Jiang · 1 shared paper, 2026 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.